ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

Core Viewpoint - ALX Oncology Holdings Inc. is set to report its second quarter 2025 financial results and provide a business update on August 12, 2025, after market close [1] Group 1: Financial Results Announcement - The company will host a teleconference in conjunction with its financial results press release [1] - The webcast for the financial results will take place on August 12, 2025, at 1:30 PM PT / 4:30 PM ET [2] - Access to the conference call can be made via phone or through a dedicated link for instant telephone access [3] Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment [4] - The lead therapeutic candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications [4] - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate expected to enter Phase 1 trials in mid-2025 [4]